## Alexander R Vartanov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/356269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. Respiratory Medicine Case Reports, 2021, 33, 101390.	0.4	3
2	High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Reports, 2021, 7, 391-394.	0.4	3
3	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia, 2021, , .	7.2	14
4	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 1312-1315.	1.3	3
5	Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL. Blood, 2019, 134, 1745-1745.	1.4	8
6	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). Blood, 2019, 134, 4291-4291.	1.4	1
7	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. Blood, 2018, 132, 4413-4413.	1.4	2
8	Controversial fluorescence <i>inÂsitu</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. British Journal of Haematology, 2015, 170, 694-703.	2.5	19
9	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Dermatology, 2014, 150, 280.	4.1	83
10	Somatic mutation as a mechanism of Wnt/Î <sup>2</sup> -catenin pathway activation in CLL. Blood, 2014, 124, 1089-1098.	1.4	65
11	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	28.9	1,202
12	Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro. Blood, 2013, 122, 4132-4132.	1.4	2
13	NF-κB Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 670-670.	1.4	5
14	Functional Somatic and Germline Variants in the NF-κB Pathway in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 560-560.	1.4	7
15	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3920-3920.	1.4	0
16	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4567-4567.	1.4	0
17	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 5-5.	1.4	1
18	<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2011, 365, 2497-2506.	27.0	1,021

#	Article	IF	CITATIONS
19	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 465-465.	1.4	Ο
20	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1438-1438.	1.4	0